Ocepek, A.; Molinari, N.; Maček, P.; Zmazek, J.; Nikolić, S.
Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis. Medicina 2026, 62, 722.
https://doi.org/10.3390/medicina62040722
AMA Style
Ocepek A, Molinari N, Maček P, Zmazek J, Nikolić S.
Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis. Medicina. 2026; 62(4):722.
https://doi.org/10.3390/medicina62040722
Chicago/Turabian Style
Ocepek, Andreja, Nikolaus Molinari, Petra Maček, Jan Zmazek, and Sara Nikolić.
2026. "Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis" Medicina 62, no. 4: 722.
https://doi.org/10.3390/medicina62040722
APA Style
Ocepek, A., Molinari, N., Maček, P., Zmazek, J., & Nikolić, S.
(2026). Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn’s Disease and Ulcerative Colitis. Medicina, 62(4), 722.
https://doi.org/10.3390/medicina62040722